aprepitant oral / Generic mfg. - LARVOL DELTA

Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention. (PubMed, Support Care Cancer) - "Single-dose netupitant maintained NK1 RO substantially longer than repeated- and single-dose aprepitant, suggesting greater potential for prolonged prevention of nausea and vomiting in ADC-treated patients. Prospective clinical validation of these model predictions would be beneficial."

Clinical • Journal • Chemotherapy-Induced Nausea and Vomiting

Aprepitant for Oculoplastic Surgeries. (PubMed, Ophthalmic Plast Reconstr Surg) - "Aprepitant demonstrated efficacy in reducing postoperative nausea and vomiting and decreasing reliance on rescue antiemetics and opioids. These findings support its potential integration into standard prophylactic regimens for postoperative nausea and vomiting prevention in oculoplastic surgery."

Clinical • Journal

APHOS 3: EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: University Hospital, Rouen | Trial completion date: Apr 2026 ➔ Jun 2027 | Trial primary completion date: Apr 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Obstructive Sleep Apnea • Pulmonary Arterial Hypertension • Respiratory Diseases • Sleep Disorder

Phase III Single-Center, Randomized Controlled, Open-Label Clinical Study of Olanzapine 5mg Combined with Standard Triple Antiemetic Regimen in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Regimens (ChiCTR) - P3 | N=200 | Recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

New P3 trial • Breast Cancer • Chemotherapy-Induced Nausea and Vomiting • Oncology • Solid Tumor

SP/NK-1 pathogenic signaling drives doxorubicin nephrotoxicity: Novel therapeutic role of MK-0869 via modulation of α-Klotho, RAS, and Wnt/β-catenin trajectories. (PubMed, Life Sci) - "In conclusion, NK-1 receptor blockade confers robust protection against Dox-induced nephrotoxicity through integrated modulation of α-Klotho signaling, RAS balance, oxidative stress, and profibrotic pathways. These findings support MK-0869 as a promising renoprotective adjunct during Dox therapy and warrant further studies to evaluate long-term safety and translational potential."

Journal • Fibrosis • Immunology • Renal Disease • B3GAT1 • CTNNB1 • FOXO3 • SOD2

Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

New P4 trial • Otorhinolaryngology

Comparison of aprepitant, dexamethasone, and ondansetron with dexamethasone and ondansetron for prevention of postoperative nausea and vomiting in high-risk patients undergoing laparoscopic surgeries: a randomized controlled trial in India. (PubMed, J Minim Invasive Surg) - "Group A received oral aprepitant 80 mg 2 hours before the surgery, and the control group received a placebo. Also, the need for rescue antiemetics was reported to be lower in patients in group A. No adverse effects were reported with any of the drugs used. The study suggests that prophylaxis with a triple antiemetic regimen consisting of aprepitant-dexamethasone-ondansetron results in a lower incidence of PONV compared with a two-drug regimen using dexamethasone-ondansetron in high-risk patients with three or more risk factors."

Journal

Oral Aprepitant for Refractory Chemotherapy-Induced Nausea and Vomiting (ASHP 2025) - No abstract available

CINV • Chemotherapy-Induced Nausea and Vomiting

Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric, investigator-initiated, open label randomized controlled trial (ASH 2025) - "Introduction The management of chemotherapy induced nausea and vomiting (CINV) during intensive inductionchemotherapy for acute myeloid leukaemia (AML) is often not optimal due to prolonged infusion ofchemotherapy over 7 days as well as omission of steroids as an anti-emetic due to concern of infections.Addition of single 3-day course of oral aprepitant with ondansetron has shown to improve vomitingcontrol in acute phase (AP), but not in delayed phase (DP) for children with AML...All patients receivedintravenous/oral ondansetron 8mg thrice daily for 10 days with first dose starting half an hour beforeinitiation of chemotherapy on day 1...Patients received a planned chemotherapy regimen ofdaunorubicin 60mg/m2 days 1-3 and continuous infusion of cytarabine 100mg/m2/day for 7 days.Targeted therapies were added along with chemotherapy or chemotherapy were interrupted ordiscontinued based on prevailing clinical scenario as per discretion of local investigator...Adverse effect..."

Clinical • Acute Myelogenous Leukemia • Chemotherapy-Induced Nausea and Vomiting • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov) - P3 | N=63 | Completed | Sponsor: University Hospital, Brest | Recruiting ➔ Completed

Trial completion • Dermatology • Myeloproliferative Neoplasm • Oncology • Pruritus

Preoperative Aprepitant Decreases Postoperative Nausea After Laparoscopic Sleeve Gastrectomy. (PubMed, R I Med J (2013)) - "The addition of preoperative aprepitant to a multimodal protocol can reduce nausea after laparoscopic sleeve gastrectomy."

Journal • Retrospective data • Gastrointestinal Disorder

A real-world study on the application of oral aprepitant combined with ondansetron in the treatment of breast cancer antibody-drug conjugates (ChiCTR) - P4 | N=100 | Not yet recruiting | Sponsor: Liaoning Cancer Hospital and Institute; Liaoning Cancer Hospital and Institute

New P4 trial • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (clinicaltrials.gov) - P3 | N=2977 | Completed | Sponsor: Jennifer Holder-Murray | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Mar 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date

Does Preoperative Aprepitant Reduce Nausea and Emesis After Orthognathic Surgery? (AAOMS 2025) - "All subjects who received a prescription were instructed to take one 40-milligram aprepitant capsule three hours prior to surgery... Preoperative aprepitant had greater influence on reducing emesis rather than nausea after orthognathic surgery. The most significant impact of aprepitant use was on subjects undergoing bimaxillary orthognathic procedures, indicating the potential benefit of a more focused approach to prescribing aprepitant."

Surgery

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (clinicaltrials.gov) - P3 | N=2500 | Recruiting | Sponsor: Jennifer Holder-Murray | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Rabin Medical Center

Checkpoint inhibition • New P1 trial • Dermatology • Oncology • Pruritus • Solid Tumor

APRE-PONV: Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: IWK Health Centre | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Sep 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Enrollment open • Trial completion date • Trial primary completion date • Anesthesia

HN-PONV-ADR-01: Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov) - P4 | N=600 | Completed | Sponsor: The First Affiliated Hospital of Zhengzhou University | Not yet recruiting ➔ Completed | Phase classification: PN/A ➔ P4 | Trial completion date: Jul 2025 ➔ Jan 2025 | Initiation date: Dec 2024 ➔ Jul 2024 | Trial primary completion date: May 2025 ➔ Dec 2024

Monotherapy • Phase classification • Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Efficacy and safety of aprepitant capsules combined with immunochemotherapy for advanced non-small cell lung cancer. (ChiCTR) - P=N/A | N=110 | Sponsor: Huai'an First People's Hospital; Huai'an First People's Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient reported outcomes with use of orally administered aprepitant in highly and moderately emetogenic (HEC and MEC) regimens (ESMO Asia 2024) - "Background NK-1 receptor antagonist aprepitant orally is given over 3 days in HEC and MEC regimens...Though administration of aprepitant provides 100% control of nausea and vomiting, real world practice data suggests otherwise. With narrowing gap in the costs of oral and i.v formulations of aprepitant, the latter must be preferred in HEC and MEC regimens to improve quality of chemotherapy delivery."

Clinical • Patient reported outcomes • Gastrointestinal Cancer • Oncology

A prospective observational study to compare the antiemetic efficacy of fosnetupitant + palonosetron vs oral aprepitant + palonosetron (ESMO Asia 2024) - "Conclusions Patients receiving FP had statistically significant lesser number of events compared to AP. With increasing access to FP, the combination must be the preferred anti-emetic regimen in HEC and MEC regimens."

Clinical • Observational data • Oncology

Comparison of Aprepitant 80mg PO 324mg IV 75mg IV in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Sleeve Gastrectomy (ASHP 2024) - No abstract available

Clinical • Gastrointestinal Disorder

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

Monotherapy • New trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Aprepitant mitigates paclitaxel-induced neuropathic pain in rats via suppressing inflammatory pathways in dorsal root ganglia. (PubMed, Drug Chem Toxicol) - "Aprepitant was orally administered every alternate day between days 2 and 14, with a prescribed dosage of 10 or 20 mg/kg. In addition, aprepitant application suppressed the protein expression of NF-kB in the dorsal root ganglia of paclitaxel-treated rats, as revealed by western blot analysis. Aprepitant treatment ameliorates neuropathy induced by paclitaxel, which is associated with decreasing proinflammatory cytokines and NF-kB expression."

Journal • Preclinical • Neuralgia • Oncology • Pain • IL1B • NFKB1 • TNFA

An exploratory study of the efficacy and safety of aprepitant and ondansetron alone or in combination in the prevention of nausea and vomiting after thyroid cancer surgery (ChiCTR) - P4 | N=600 | Not yet recruiting | Sponsor: First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University

New P4 trial • Surgery • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma